Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
61. |
ECCT/17/03/01 | The POWER cohort A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women |
Principal Investigator(s) 1. Dr. Stella Njuguna Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county) |
04-05-2017 |
View |
62. |
ECCT/15/06/02 | ZINC in Sickle cell study The effects of Zinc supplementation in children with sickle cell disease in Western Kenya: a pilot study. |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya Health Facilities in Western Kenya |
17-08-2015 |
View |
63. |
ECCT/12/09/03 | REALITY Trial Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy |
Principal Investigator(s) 1. DR ANTHONY OLIWA ETYANG Site(s) in Kenya 1. KEMRI Wellcome Trust Research Programme (Kilifi county) 2. Moi University School of Medicine, Academic Model for the Prevention and Treatment of HIV/AIDS (AMPATH) Centre at Moi Teaching Referral Hospital (MTRH) (Uasin Gishu county) |
05-07-2012 |
View |
64. |
ECCT/20/09/01 | PrEP in Pharmacy - PILOT STUDY Pharmacy delivery to expand the reach of PrEP in Kenya: Pilot study |
Principal Investigator(s) 1. Kenneth Kairu Ngure Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
28-10-2020 |
View |
65. |
ECCT/23/02/05 | Pharmacy PrEP cRCT Pharmacy delivery to expand the reach of PrEP in Kenya: cluster-randomized control trial |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Kenneth Ngure Site(s) in Kenya 1. Kenya Medical Research Institute, Center for Microbiology Research, Research Care and Training Programme (KEMRI-CMR-RCTP) research center (Kisumu county) 2. Kenya Medical Research Institute, Center for Clinical Research, Partners in Health and Research Development (KEMRI-CCR-PHRD) research center (Kiambu county) |
07-06-2023 |
View |
66. |
ECCT/11/08/04 | SSG/PM Pharmacovigilance Plan Pharmacovigilance Plan to Monitor the Safety and Effectiveness of Combination of Sodium Stibogluconate and Paramomycin in the Treatment of Visceral Leishmaniasis The SSG/PM (Sodium Stibogluconate/Paromycin) Pharmacovigilance Plan aims to collect pharmacovigilance information during the early post-approval period of SSG/PM as soon as SSG/PM is in use by the Ministries of Health for treatment of Visceral Leishmaniasis. During the early post-approval period, SSG/PM might be used in settings different from clinical trials and a much larger and diverse population might be exposed in a relatively short timeframe. The pharmacovigilance (PV) programme is crucial in order to continuously evaluate the risk-benefit ratio in different groups of patients and in different contexts The Pharmacovigilance study in Kenya involves the key sentinel site of Kacheliba kala-azar treatment centre, (where MSF-OCG is based). A similar protocol is ongoing in Sudan and planned for Uganda. The Pharmacovigilance plan primary objectives are: a) to continuously monitor the safety profile of SSG/PM during the first 2 years that follow its authorization for use in East Africa; b) to identify additional risks that have not been reported in pre-approval clinical studies; c) to determine whether SSG/PM adverse reactions are of higher concern in specific groups of patients; d) to monitor the treatment failure rate of SSG/PM and e) to monitor any evidence in site variation in terms of SSG/PM effectiveness and safety. The target population are all VL patients treated with SSG/PM in Kenya and other participating countries. A registry is used independently from clinical presentation and demographic characteristics. Diagnostic, treatment and discharge procedures are consistent with the routine clinical practice in use in the health facility. A standard form is used to collect information. No blood/tissue samples or extra medical procedures are required for the PV plan. Every 3 months, descriptive statistics are produced. In particular, the total number of SAE, the number of treatment-related SAE and the number of treatment failures are calculated. The Steering Committee is responsible for data review. In Kenya Ethical and Regulatory approval is sought through KEMRI ERC and Pharmacy and Poisons Board. Informed consent document is distributed to each patient treated with SSG/PM. The aim of the PV plan is discussed, as well as the measures taken to ensure confidentiality of the data collected. |
Principal Investigator(s) 1. Monique Wasunna Site(s) in Kenya 1. Kacheliba Kala-azar treatment centre (West Pokot county) 2. Kimalel Health Centre (Baringo county) |
13-05-2012 |
View |
67. |
ECCT/24/02/05 | Doxo-study Pharmacokinetic profiles for Doxorubicin among children with childhood cancer in Kenya. |
Principal Investigator(s) 1. Festus MUIGAI Njunguna Site(s) in Kenya MOI UNIVERSITY SCHOOL OF MEDICINE |
20-09-2024 |
View |
68. |
ECCT/21/08/02 | IPrEP Men\'s Study IPrEP Men’s Study: Expanding the reach of prevention for men in Kisumu, Kenya |
Principal Investigator(s) 1. Kawango Agot 2. Wafaa El-Sadr Site(s) in Kenya Kisumu Impact Research and Development Organization (K-IRDO) CRS |
11-11-2021 |
View |
69. |
ECCT/18/03/01 | JiPime JiPrEP (HIVST Study) HIV self-testing to improve the efficiency of PrEP delivery. |
Principal Investigator(s) 1. Kenneth Kairu Ngure Site(s) in Kenya KEMRI-CCR PHRD (THIKA) |
16-05-2018 |
View |
70. |
ECCT/17/05/02 | The Anza Mapema Study Expanding test and treat for HIV prevention in MSM in Kisumu, Kenya: The Anza Mapema Study |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno Site(s) in Kenya Anza Mapema Study Clinic |
01-09-2017 |
View |